Q3-osavuosiraportti
10 päivää sitten‧33 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
119 737
Myynti
Määrä
102 473
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 000 | - | - | ||
| 93 | - | - | ||
| 316 | - | - | ||
| 1 543 | - | - | ||
| 6 457 | - | - |
Ylin
2,985VWAP
Alin
2,85VaihtoMäärä
4,1 1 399 526
VWAP
Ylin
2,985Alin
2,85VaihtoMäärä
4,1 1 399 526
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 19.5. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16 t sittenAscelia Pharma announces FDA's acceptance of Orviglance's New Drug Application for review 15.11.2025, 10.15 0 likes 0 dislikes Ascelia Pharma Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people living with rare cancer diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3. July 2026 under the Prescription Drug User Fee Act (PDUFA). Through its 'day 74 letter', the FDA has confirmed its acceptance of the NDA application for Orviglance and continuation of the review, aiming for a decision by 3. July 2026 as the PDUFA date. "This milestone represents another important step towards our goal of making Orviglance available to cancer patients with impaired renal function. We look forward to continuing to work with the FDA throughout the review process," says Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA's application acceptance is also important for our discussions with potential commercialization partners."
·4.11.Is anyone positive about tomorrow?
·4.11.No, not really. Expect a rather neutral report without surprises. The primary trigger I'm waiting for is a partner. If the partnership agreement is reasonably good, there's a lot to gain here going forward. FDA is of course also a trigger, but there's still some time until the final answer.- ·26.10.Ascelia Pharma – Presentation of interim Q3 2025 report By HC Andersen Capital 06.11.2025, 12.00 https://www.inderes.dk/videos/ascelia-pharma-presentation-of-interim-q3-2025-report
·16.10.Unbelievable that the price is only 3.025 when about 1 month ago there was a closed issue where subscriptions were made at a price of 3.5 and thus capital was secured for Q4 NEXT YEAR and those who subscribed to a closed issue are often those who follow the company extra closely and deeply. Price 3.5 is therefore about 16% higher than today's current price......so I would say that the price should currently be at least 3.5 and actually also a little higher because this security for liquidity is probably MORE than 12 months in advance.·17.10.They have said they are negotiating. I also have my doubts whether there have been serious negotiations about a partnership. But a lot can be discussed in a month, so a partnership can come "when it is supposed to be". I don't feel (due to their presentations and the private placement) that it is just around the corner. It should also be a good deal, and it sounds like they are serious and are committed to making it not just a partner, but one where we as shareholders can also be satisfied. It is probably most likely that the next thing we hear is the quarterly financial statements and then the FDA's receipt and indication of when they will come up with an answer. As long as they have money in the coffers, I have enough time.- ·10.10.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
10 päivää sitten‧33 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 t sittenAscelia Pharma announces FDA's acceptance of Orviglance's New Drug Application for review 15.11.2025, 10.15 0 likes 0 dislikes Ascelia Pharma Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people living with rare cancer diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3. July 2026 under the Prescription Drug User Fee Act (PDUFA). Through its 'day 74 letter', the FDA has confirmed its acceptance of the NDA application for Orviglance and continuation of the review, aiming for a decision by 3. July 2026 as the PDUFA date. "This milestone represents another important step towards our goal of making Orviglance available to cancer patients with impaired renal function. We look forward to continuing to work with the FDA throughout the review process," says Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA's application acceptance is also important for our discussions with potential commercialization partners."
- ·4.11.Is anyone positive about tomorrow?·4.11.No, not really. Expect a rather neutral report without surprises. The primary trigger I'm waiting for is a partner. If the partnership agreement is reasonably good, there's a lot to gain here going forward. FDA is of course also a trigger, but there's still some time until the final answer.
- ·26.10.Ascelia Pharma – Presentation of interim Q3 2025 report By HC Andersen Capital 06.11.2025, 12.00 https://www.inderes.dk/videos/ascelia-pharma-presentation-of-interim-q3-2025-report
- ·16.10.Unbelievable that the price is only 3.025 when about 1 month ago there was a closed issue where subscriptions were made at a price of 3.5 and thus capital was secured for Q4 NEXT YEAR and those who subscribed to a closed issue are often those who follow the company extra closely and deeply. Price 3.5 is therefore about 16% higher than today's current price......so I would say that the price should currently be at least 3.5 and actually also a little higher because this security for liquidity is probably MORE than 12 months in advance.·17.10.They have said they are negotiating. I also have my doubts whether there have been serious negotiations about a partnership. But a lot can be discussed in a month, so a partnership can come "when it is supposed to be". I don't feel (due to their presentations and the private placement) that it is just around the corner. It should also be a good deal, and it sounds like they are serious and are committed to making it not just a partner, but one where we as shareholders can also be satisfied. It is probably most likely that the next thing we hear is the quarterly financial statements and then the FDA's receipt and indication of when they will come up with an answer. As long as they have money in the coffers, I have enough time.
- ·10.10.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
119 737
Myynti
Määrä
102 473
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 000 | - | - | ||
| 93 | - | - | ||
| 316 | - | - | ||
| 1 543 | - | - | ||
| 6 457 | - | - |
Ylin
2,985VWAP
Alin
2,85VaihtoMäärä
4,1 1 399 526
VWAP
Ylin
2,985Alin
2,85VaihtoMäärä
4,1 1 399 526
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 19.5. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
10 päivää sitten‧33 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4-osavuosiraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 6.11. | |
| 2025 Q3-osavuosiraportti | 5.11. | |
| 2025 Q2-osavuosiraportti | 22.8. | |
| 2025 Q2-osavuosiraportti | 21.8. | |
| 2025 Q1-osavuosiraportti | 19.5. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 t sittenAscelia Pharma announces FDA's acceptance of Orviglance's New Drug Application for review 15.11.2025, 10.15 0 likes 0 dislikes Ascelia Pharma Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people living with rare cancer diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3. July 2026 under the Prescription Drug User Fee Act (PDUFA). Through its 'day 74 letter', the FDA has confirmed its acceptance of the NDA application for Orviglance and continuation of the review, aiming for a decision by 3. July 2026 as the PDUFA date. "This milestone represents another important step towards our goal of making Orviglance available to cancer patients with impaired renal function. We look forward to continuing to work with the FDA throughout the review process," says Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA's application acceptance is also important for our discussions with potential commercialization partners."
- ·4.11.Is anyone positive about tomorrow?·4.11.No, not really. Expect a rather neutral report without surprises. The primary trigger I'm waiting for is a partner. If the partnership agreement is reasonably good, there's a lot to gain here going forward. FDA is of course also a trigger, but there's still some time until the final answer.
- ·26.10.Ascelia Pharma – Presentation of interim Q3 2025 report By HC Andersen Capital 06.11.2025, 12.00 https://www.inderes.dk/videos/ascelia-pharma-presentation-of-interim-q3-2025-report
- ·16.10.Unbelievable that the price is only 3.025 when about 1 month ago there was a closed issue where subscriptions were made at a price of 3.5 and thus capital was secured for Q4 NEXT YEAR and those who subscribed to a closed issue are often those who follow the company extra closely and deeply. Price 3.5 is therefore about 16% higher than today's current price......so I would say that the price should currently be at least 3.5 and actually also a little higher because this security for liquidity is probably MORE than 12 months in advance.·17.10.They have said they are negotiating. I also have my doubts whether there have been serious negotiations about a partnership. But a lot can be discussed in a month, so a partnership can come "when it is supposed to be". I don't feel (due to their presentations and the private placement) that it is just around the corner. It should also be a good deal, and it sounds like they are serious and are committed to making it not just a partner, but one where we as shareholders can also be satisfied. It is probably most likely that the next thing we hear is the quarterly financial statements and then the FDA's receipt and indication of when they will come up with an answer. As long as they have money in the coffers, I have enough time.
- ·10.10.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
119 737
Myynti
Määrä
102 473
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 000 | - | - | ||
| 93 | - | - | ||
| 316 | - | - | ||
| 1 543 | - | - | ||
| 6 457 | - | - |
Ylin
2,985VWAP
Alin
2,85VaihtoMäärä
4,1 1 399 526
VWAP
Ylin
2,985Alin
2,85VaihtoMäärä
4,1 1 399 526
Välittäjätilasto
Dataa ei löytynyt